Confronting the emerging epidemic of hcv infection among young injection drug users

American Journal of Public Health

Volumn 104, Issue 5, 2014, Pages 816-821

  Valdiserri, Ronald ^a   Khalsa, Jag ^b   Dan, Corinna ^a   Holmberg, Scott ^d   Zibbell, Jon ^d   Holtzman, Deborah ^d   Lubran, Robert ^c   Compton, Wilson ^b  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; EPIDEMIC; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MALE; MASS SCREENING; OPIATE ADDICTION; PRIMARY PREVENTION; PUBLIC HEALTH; RESEARCH; SENTINEL SURVEILLANCE; SEX RATIO; SUBSTANCE ABUSE; UNITED STATES;

ADOLESCENT; AGE DISTRIBUTION; EPIDEMICS; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; MALE; MASS SCREENING; OPIOID-RELATED DISORDERS; PRIMARY PREVENTION; PUBLIC HEALTH; RESEARCH; SENTINEL SURVEILLANCE; SEX DISTRIBUTION; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 84898670718     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2013.301812     Document Type: Article

References (50)

1. Ly KN, Xing J, Klevens M, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999-2007. Ann Intern Med. 2012;156(4):271-278.
2. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
3. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(suppl 1):S3-S9.
4. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-1055.
5. Rein DB, Wittenborn JS, Weinbaum CM, et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72.
6. Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press 2010.
7. Centers for Disease Control and Prevention. Viral hepatitis surveillance-United States, 2010. Available at: http://www.cdc.gov/hepatitis/Statistics/ 2010Surveillance/Commentary.htm. Accessed March 25, 2013.
8. Centers for Disease Control and Prevention. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users-New York, November 2004, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(19):517-521.
9. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537-541.
10. Centers for Disease Control and Prevention. Hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep. 2012;61 (19):358.
11. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144 (10):705-714.
12. Centers for Disease Control and Prevention. Risk factors for hepatitis C virus infections among young adults-Massachusetts, 2010. MMWR Morb MortalWkly Rep. 2011;60(42):1457-1458.
13. Havens JR, Lofwall MR, Frost SD, et al. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44-e52.
14. Pollini RA, Banta-Green CJ, Cuevas-Mota J, et al. Problematic use of prescription-type opioids prior to heroin use among young injectors. Subst Abuse Rehabil. 2011;2(1):173-180.
15. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83(suppl 1):S4-S7.
16. McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33(10):1297-1305.
17. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-107.
18. Substance Abuse and Mental Health Services Administration. Results From the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658.
19. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavioral surveillance-United States, 2011. MMWR Surveill Summ. 2012;61(4):1-162.
20. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37-44.
21. Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107(3): 587-596.
22. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011; vol. 23. Available at: http:// www.cdc.gov/hiv/topics/surveillance/resources/reports. Accessed April 29, 2013.
23. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005- 2010. MMWR Morb Mortal Wkly Rep. 2011;60(28): 945-950.
24. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 suppl 1): S210-S219.
25. Grebely J, Morris MD, Rice TM, et al. Cohort profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. Int J Epidemiol. 2013;42(6):1649-1659.
26. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36(3):737-742.
27. Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA. 2002;287(18):2406-2413.
28. Hagan H, Pouget ER, Williams IT, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis. 2010;201(3): 378-385.
29. Mehta SH, Astemborski J, Kirk GD, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis. 2011;203(5):587-594.
30. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74-83.
31. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645-653.
32. Martin NK, Vikcerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6): 1137-1144.
33. Center for Substance Abuse Treatment. Medication- Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. HHS Publication No. (SMA) 12-4214.
34. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155-166.
35. Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37 (4):426-430.
36. Cheever LW, Kresina TF, Cajina A, Lubran R. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56(suppl 1):S3-S6.
37. Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22(2):171-176.
38. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333.
39. Substance Abuse and Mental Health Services Administration. An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. Advisory. 2012;11(1).
40. Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. J Adolesc Health. 2012;51(1):6-17.
41. Wu LT, Blazer DG, Li TK, Woody GE. Treatment use and barriers among adolescents with prescription opioid use disorders. Addict Behav. 2011;36(12): 1233-1239.
42. Martino S, Brigham GS, Higgins C, et al. Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. J Subst Abuse Treat. 2010;38(suppl 1): S31-S43.
43. Henggeler SW, Halliday-Boykins CA, Cunningham PB, et al. Juvenile drug court: enhancing outcomes by integrating evidence-based treatments. J Consult Clin Psychol. 2006;74(1):42-54.
44. Barry CL, Huskamp HA. Moving beyond parity- mental health and addiction care under the ACA. N Engl J Med. 2011;365(11):973-975.
45. Moyer VA, US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Service Task Force recommendation statement. Ann Intern Med. 2013;159(5):349-357.
46. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368 (20):1907-1917.
47. US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care & treatment of viral hepatitis. Available at: http://www.hhs.gov/ash/ initiatives/hepatitis/actionplanviralhepatitis2011.pdf. Accessed March 25, 2013.
48. Singer M. AIDS and the health crisis of the U.S. urban poor; the perspective of critical medical anthropology. Soc Sci Med. 1994;39(7):931-948.
49. Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423-441.
50. Gonzàlez-Guarda RM, Florom-Smith AL, Thomas T. A syndemic model of substance abuse, intimate partner violence, HIV infection, and mental health among Hispanics. Public Health Nurs. 2011;28(4):366-378.